March 23, 2023
Health Canada Approves First Treatment Option for Generalized Pustular Psoriasis Flares in Adults
January 25, 2023
University Health Network and Boehringer Ingelheim Canada Partner to Impact Patients Lives and Help a Healthcare System Under Strain
December 7, 2022
Phase III Trial Demonstrated Jardiance® is the First SGLT2 Inhibitor to Show Statistically Significant Reduction in Blood Sugar Levels in Children and Adolescents with Type 2 Diabetes
No current content.
Connect with us LinkedIn